| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H30N2O2 |
| Molecular Weight | 354.4858 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCCCCOC1=C2COCC2=C(CC3=CC=CC=C3)N=C1C
InChI
InChIKey=KXSKBNFNSAMNEZ-UHFFFAOYSA-N
InChI=1S/C22H30N2O2/c1-16(2)23-11-7-8-12-26-22-17(3)24-21(19-14-25-15-20(19)22)13-18-9-5-4-6-10-18/h4-6,9-10,16,23H,7-8,11-15H2,1-3H3
Barucainide, an IB anti-arrhythmic agent, was evaluated in patients with coronary artery disease. Its antiarrhythmic effect was studied in patients with markedly depressed left-ventricular function. Barucainide was in phase II clinical trials to treat the patients with arrhythmias but the development of the drug was discontinued.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
The pharmacokinetic behavior of the class Ib antiarrhythmic drug barucainide was investigated in a phase I study in a group of 6 healthy male volunteers after oral administration of an initial single dose of 20 mg and incremental doses between 30 and 70 mg barucainide hydrochloride.
Route of Administration:
Oral
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
